日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)

采用多药化疗治疗的局限性胰腺腺癌中生长分化因子-15 (GDF-15)：来自 NEOLAP 试验 (AIO-PAK-0113) 的生物标志物分析

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100274
Kimmel, B; Löhnert, S T; Wedekink, F; Günther, M; Ormanns, S; Hartlapp, I; Siveke, J; Siegler, G; Boeck, S; Algül, H; Martens, U; Kullmann, F; Ettrich, T; Held, S; Anger, F; Germer, C-T; Heinemann, V; Wischhusen, J; Kunzmann, V
GDF-15
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]

对“CA 19-9 在接受多药诱导化疗的局部晚期胰腺癌中的预后和预测价值：一项前瞻性、多中心 II 期试验 (NEOLAP-AIO-PAK-0113) 的结果”的更正：[ESMO Open 7 (2024) 100552]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103463
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V
SMO
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]

对“CA 19-9 在局部晚期胰腺癌多药诱导化疗中的预后和预测价值：一项前瞻性、多中心 II 期试验 (NEOLAP-AIO-PAK-0113) 的结果”的更正：[ESMO Open 7 (2024) 100552]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103705
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V
SMO
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Can Deliberative Participatory Fora Cure Representation Gaps in France and Germany?

协商参与式论坛能否解决法国和德国的代表性差距问题？

期刊:
影响因子:
doi:10.1007/s11615-022-00452-0
Blome, Agnes; Hartlapp, Miriam
发表日期：2023
文献求助 收藏

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

CA 19-9 在接受多药诱导化疗的局部晚期胰腺癌中的预后和预测价值：一项前瞻性、多中心 II 期试验 (NEOLAP-AIO-PAK-0113) 的结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100552
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V
胰腺癌
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

并发胆汁淤积是否会改变胰头腺癌患者术前血清 CA19-9 水平升高的预后价值？

期刊:Annals of Surgical Oncology
影响因子:3.5
doi:10.1245/s10434-022-12460-w
Anger, Friedrich; Lock, Johan Friso; Klein, Ingo; Hartlapp, Ingo; Wiegering, Armin; Germer, Christoph-Thomas; Kunzmann, Volker; Löb, Stefan
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

局部晚期不可切除胰腺癌患者接受强化新辅助化疗（紫杉醇白蛋白结合型联合吉西他滨）后序贯FOLFIRINOX方案治疗

期刊:Case Reports in Oncology
影响因子:0.7
doi:10.1159/000367966
Kunzmann, Volker; Herrmann, Ken; Bluemel, Christina; Kapp, Markus; Hartlapp, Ingo; Steger, Ulrich
胰腺癌
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Dexverapamil to overcome epirubicin resistance in advanced breast cancer

右维拉帕米可克服晚期乳腺癌的表柔比星耐药性

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/BF02351063
Thürlimann, B; Kröger, N; Greiner, J; Mross, K; Schüller, J; Schernhammer, E; Schumacher, K; Gastl, G; Hartlapp, J; Kupper, H
肿瘤
肿瘤免疫
乳腺癌
发表日期：1995
文献求助 收藏